Ampio Pharmaceuticals, Inc.

1.68 USD
-0.17 (-9.19%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Ampio Pharmaceuticals, Inc. stock is up 3.7% since 30 days ago. The next earnings date is Mar 25, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 35.71% of the previous 13 February’s closed higher than January.

About Ampio Pharmaceuticals, Inc.

Ampio Pharmaceuticals, Inc. focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial. AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation, AP-019, an Inhaled Ampion treatment.